Safety and efficacy of weekly somapacitan for growth hormone deficiency in children

References

1. 1.↵
   1. Brinkman JE

   . Physiology, growth hormone. [Updated 2023; accessed 2024 Aug 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482141/
2. 2.↵
   1. Murray PG,
   2. Clayton PE

   . Disorders of growth hormone in childhood. [Updated 2022; accessed 2024 Aug 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278971/
3. 3.↵
   1. Leong A,
   2. Wong JSL,
   3. Selveindran NM,
   4. Mat Noji HM,
   5. Fong SY,
   6. Riduan AI, et al.

   Compliance to growth hormone therapy in children and adolescents with growth hormone deficiency and Turner syndrome and impact on height velocity: a prospective study. Malaysian J Paediatr Child Health 2022; 28: 16-28.

   OpenUrl
4. 4.↵
   1. Miller BS,
   2. Blair JC,
   3. Rasmussen MH,
   4. Maniatis A,
   5. Kildemoes RJ,
   6. Mori J, et al.

   Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab 2022; 107: 3378-3388.

   OpenUrlPubMed
5. 5.↵
   1. Paton DM

   . Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency. Drugs Today (Barc) 2022; 58: 509-517.

   OpenUrlPubMed
6. 6.↵
   1. Sävendahl L,
   2. Battelino T,
   3. Højby Rasmussen M,
   4. Brod M,
   5. Röhrich S,
   6. Saenger P, et al.

   Weekly somapacitan in GH deficiency: 4-year efficacy, safety, and treatment/disease burden results from REAL 3. J Clin Endocrinol Metab 2023; 108: 2569-2578.

   OpenUrlPubMed
7. 7.↵
   1. Miller BS,
   2. Blair JC,
   3. Rasmussen MH,
   4. Maniatis A,
   5. Mori J,
   6. Böttcher V, et al.

   Effective GH replacement with somapacitan in children with GHD: REAL4 2-year results and after switch from daily GH. J Clin Endocrinol Metab 2023; 108: 3090-3099.

   OpenUrlPubMed
8. 8.↵
   1. Rogol AD,
   2. Hayden GF

   . Etiologies and early diagnosis of short stature and growth failure in children and adolescents. J Pediatr 2014; 164: S1-S14.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Henry RK,
   2. Mamilly L,
   3. Chaudhari M,
   4. Klamer BG,
   5. Nikahd M,
   6. Pyle-Eilola AL

   . Beyond the bias! Gender distribution in paediatric growth hormone deficiency reexamined. Clin Endocrinol (Oxf) 2024; 100: 441-446.

   OpenUrlPubMed
10. 10.↵
    1. Rahman MS,
    2. Howlader T,
    3. Masud MS,
    4. Rahman ML

    . Association of low-birth weight with malnutrition in children under 5 years in Bangladesh: do mother’s education, socio-economic status, and birth interval matter? PLoS One 2016; 11: e0157814.

    OpenUrlPubMed
11. 11.↵
    1. Emmanuel M,
    2. Bokor BR

    . Tanner stages. [Updated 2022; 2022 Dec 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/29262142/
12. 12.↵
    1. Sävendahl L,
    2. Battelino T,
    3. Højby Rasmussen M,
    4. Brod M,
    5. Saenger P,
    6. Horikawa R

    . Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3. J Clin Endocrinol Metab 2022; 107: 1357-1367.

    OpenUrlPubMed
13. 13.↵
    1. Mori J,
    2. Ohata Y,
    3. Fujisawa Y,
    4. Sato Y,
    5. Röhrich S,
    6. Rasmussen MH, et al.

    Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: results from REAL4, a phase 3 clinical trial. Clin Endocrinol (Oxf) 2024; 100: 389-398.

    OpenUrlPubMed
14. 14.↵
    1. Miller BS,
    2. Blair JC,
    3. Rasmussen MH,
    4. Maniatis A,
    5. Kildemoes RJ,
    6. Mori J, et al.

    Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab 2022; 107: 3378-3388.

    OpenUrlPubMed
15. 15.↵
    1. Zhu J,
    2. Yuan K,
    3. Rana S,
    4. Jakki SL,
    5. Bhat AS,
    6. Liang L, et al.

    Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis. Sci Rep 2024; 14: 8061.

    OpenUrlPubMed
16. 16.↵
    1. Thornton PS,
    2. Maniatis AK,
    3. Aghajanova E,
    4. Chertok E,
    5. Vlachopapadopoulou E,
    6. Lin Z, et al.

    Response to letter to the editor from Sävendahl et al: “Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: the phase 3 heiGHt trial”. J Clin Endocrinol Metab 2022; 107: e1333-e1334.

    OpenUrlPubMed